Ignite Creation Date:
2024-05-06 @ 6:54 PM
Last Modification Date:
2024-10-26 @ 2:57 PM
Study NCT ID:
NCT05829317
Status:
RECRUITING
Last Update Posted:
2023-11-18
First Post:
2023-03-15
Brief Title:
Magnesium Prophylaxis for the Prevention of New-Onset Atrial Fibrillation in Critically Ill Patients
Sponsor:
Queens University
Organization:
Queens University
Study Overview
Official Title:
Parenteral Magnesium Prophylaxis for the Prevention of New-Onset Atrial Fibrillation in Critically Ill Patients - a Pilot Feasibility Study
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ATOMIC
Brief Summary:
A double-blind multi-centre randomized placebo-controlled feasibility pilot trial in the prevention of new onset atrial fibrillation of critically ill patients admitted to an ICU
Detailed Description:
Most studies of new onset atrial fibrillation NOAF in critical illness focus on treatment of this arrhythmia but this innovative study will focus on prevention Parenteral Mg is a low cost and readily available treatment that may be beneficial for reducing the incidence of NOAF in critically ill patients with the potential to improve patient centred outcomes and provide a cost effective prophylaxis The main outcome of this study is to determine if it is feasible to conduct a randomized controlled trial comparing parenteral magnesium sulfate with placebo for the prophylaxis of new onset atrial fibrillation in critically ill patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None